- Live Vaccines
- Cell free PA Vaccines
Anthrax Vaccine Market size was valued at USD 10.67 billion in 2022 and it is estimated to reach at a USD 11.83 billion in 2029, growing at a significant CAGR of 7.5% from 2023-29. Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. The market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost-effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA-approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.
The Anthrax Vaccine Market is growing at a CAGR of 7.5% over the Forecast Period
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Emergent BioSolutions , Elusys Therapeutics, Panacea Biotec, Zoetis, Bayer, Colorado Serum Company, Inc, Biogénesis Bago, Emergent BioSolutions, Porton Biopharma Ltd, Merial, Merck, Altimmune, Inc. PharmAthene US Corp, Agrovet, CAVAC, Centro Diagnóstico Veterinario, Ceva Sante Animale
1.Executive Summary |
2.Global Anthrax Vaccine Market Introduction |
2.1.Global Anthrax Vaccine Market - Taxonomy |
2.2.Global Anthrax Vaccine Market - Definitions |
2.2.1.Basis Of Type |
2.2.2.End User |
2.2.3.Region |
3.Global Anthrax Vaccine Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Anthrax Vaccine Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Anthrax Vaccine Market By Basis Of Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Live Vaccines |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Cell free PA Vaccines |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Anthrax Vaccine Market By End User , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Hospitals |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Clinics |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Vaccination Centers |
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Anthrax Vaccine Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. Basis Of Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Live Vaccines |
8.1.2.Cell free PA Vaccines |
8.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospitals |
8.2.2.Clinics |
8.2.3.Vaccination Centers |
8.2.4.Others |
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Live Vaccines |
9.1.2.Cell free PA Vaccines |
9.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospitals |
9.2.2.Clinics |
9.2.3.Vaccination Centers |
9.2.4.Others |
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
9.3.7. |
10.Asia Pacific (APAC) Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Live Vaccines |
10.1.2.Cell free PA Vaccines |
10.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospitals |
10.2.2.Clinics |
10.2.3.Vaccination Centers |
10.2.4.Others |
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Live Vaccines |
11.1.2.Cell free PA Vaccines |
11.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospitals |
11.2.2.Clinics |
11.2.3.Vaccination Centers |
11.2.4.Others |
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Live Vaccines |
12.1.2.Cell free PA Vaccines |
12.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospitals |
12.2.2.Clinics |
12.2.3.Vaccination Centers |
12.2.4.Others |
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Emergent BioSolutions , |
13.2.2.Elusys Therapeutics , |
13.2.3.Porton Biopharma Limited , |
13.2.4.Panacea Biotec, |
13.2.5.Zoetis, |
13.2.6.Bayer, |
13.2.7.Emergent BioSolutions, |
13.2.8.Merial, Merck, |
13.2.9.Altimmune, Inc. |
13.2.10.PharmAthene US Corp, |
13.2.11.Agrovet, |
13.2.12.CAVAC, |
14. Research Methodology |
15. Appendix and Abbreviations |